-
The American Journal of Emergency... Feb 2021This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo. (Comparative Study)
Comparative Study
BACKGROUND
This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo.
METHODS
A prospective, double-blind, randomized clinical trial was performed on patients who presented to the emergency department (ED) with nausea and vertigo in the six month period between Nov 1st 2012 and May 1st 2013. Adult patients who were 18 to 65 years old presenting to the ED with nausea and vertigo or motion sickness were included in the study. A total of 200 patients were divided into 2 groups who were admitted to ED with complaints of vertigo accompanied by nausea. In the first group, 50 mg dimenhydrinate and 10 mg metoclopramide infusions were given intravenously for 15 min. The efficacy of treatment was measured by using a 10 mm Visual Analog Scale (VAS) performed at 0, 15 and the 30th minute. The primary outcome variable was a reduction in vertigo intensity documented on the VAS at the 30th minute after medication administration.
RESULTS
A total of 200 patients were included in the randomization (n=100 in both groups). The baseline vertigo VAS scores were 7.57±1.42 in the dimenhydrinate (DMT) group and 7.27±1.40 in the metoclopramide (MTP) group (p=0.09). In the 30th minute of treatment, the average vertigo VAS score was 2.46 ± 2.39 in the DMT group and 2.31±1.96 in the MTP group; no significant differences were detected between groups. The baseline nausea VAS scores were 7.62±1.48 in the DMT group and 7.45±1.27 in the MTP group (p=0.36). In the 30th minute of treatment the average vertigo VAS score decreased to 2.27±2.24 in the DMT group and 2.70±2.48 in the MTP group, no significant differences were detected between groups. No significant differences were detected between nausea VAS changes and vertigo VAS changes at 30th minutes of the treatment (p=0.06, p=0.85 respectively). Rescue medication need was similar in both treatment groups (p=0.94). No significant differences were detected about the side effects which are sedation (p=0.56) and hypotension (p=0.57).
CONCLUSIONS
In conclusion, this prospective, double-blind, randomized study showed that both DMT and MTP have similar efficacy in reducing nausea and vertigo symptoms in the ED.
Topics: Adolescent; Adult; Aged; Antiemetics; Dimenhydrinate; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Prospective Studies; Vertigo
PubMed: 33360021
DOI: 10.1016/j.ajem.2020.12.010 -
Allergologia Et Immunopathologia 2012
Topics: Antiemetics; Diagnosis, Differential; Dimenhydrinate; Drug Hypersensitivity; Female; Histamine Antagonists; Histamine H1 Antagonists; Humans; Middle Aged; Skin Tests; Urticaria
PubMed: 21889831
DOI: 10.1016/j.aller.2011.05.009 -
Canadian Journal of Anaesthesia =... Aug 2000Dimenhydrinate and metoclopramide are inexpensive antiemetic drugs. Metoclopramide, especially, has been studied extensively in the past, but there are no studies on the... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
PURPOSE
Dimenhydrinate and metoclopramide are inexpensive antiemetic drugs. Metoclopramide, especially, has been studied extensively in the past, but there are no studies on the combination of both drugs for prevention of postoperative nausea and vomiting (PONV).
METHODS
One hundred and sixty male inpatients undergoing endonasal surgery were randomized to receive one of four antiemetic regimens in a double-blind manner: placebo, 1 mg x kg(-1) dimenhydrinate, 0.3 mg x kg(-1) metoclopramide, or the combination of both drugs was administered after induction of anesthesia. Patients received a second dose of these drugs six hours after the first administration to mitigate their short half-life. Standardized general anesthesia included benzodiazepine premedication, propofol, desflurane in N2O/O2 vecuronium, and a continuous infusion of remifentanil. Postoperative analgesia and antiemetic rescue medication were standardized. Episodes of vomiting, retching, nausea, and the need for additional antiemetics were recorded for 24 hr. The incidences of PONV were analyzed with Fisher's Exact test and the severity of PONV (rated by a standardized scoring algorithm) with the Jonckheere-Terpestra-test.
RESULTS
The incidence of patients free from PONV was 62.5% in the placebo-group and increased to 72.5% in the metoclopramide-group (P = 0.54), 75.0% in the dimenhydrinate-group (P = 0.34), and 85.0% in the combination- group (P = 0.025). In the latter group, the severity of PONV was reduced compared with placebo treatment (P = 0.017; Jonckheere-Terpestra-test).
CONCLUSION
Dimenhydrinate and metoclopramide were ineffective in reducing the incidence and the severity of PONV. Their combination reduced the incidence of PONV compared with placebo.
Topics: Adult; Aged; Antiemetics; Dimenhydrinate; Double-Blind Method; Drug Therapy, Combination; Humans; Incidence; Male; Metoclopramide; Middle Aged; Nose; Postoperative Nausea and Vomiting
PubMed: 10958095
DOI: 10.1007/BF03019481 -
Scientific Reports Aug 2023Orphenadrine (ORP), dimenhydrinate (DMN), and cinnarizine (CNN) were investigated using green-sensitive spectrofluorometric methods. Method, I used for determination of...
Orphenadrine (ORP), dimenhydrinate (DMN), and cinnarizine (CNN) were investigated using green-sensitive spectrofluorometric methods. Method, I used for determination of DMN in 0.1 M hydrochloric acid (HCl) and 1.0% sodium dodecyl sulphate (SDS) at 286 nm after λ 222 nm, while for determination of ORP in 1.0% w/v SDS involves measuring the fluorescence at 285 nm after λ 220 nm. For DMN and ORP, the detection and quantitation limits were 2.99 and 4.71 and 9.08 and 14.29 ng/mL, respectively. The ranges of DMN and ORP were 0.10-1.0 and 0.04-0.5 µg/mL, respectively, in micellar aqueous solution. Method II, the derivative intensities of DMN and CNN were measured at a fixed of different wavelength between the excitation and the emission wavelengths (Δλ) = 60 nm at 282 and 322 nm, at the zero crossing of each other, respectively. The detection and quantitation limits for DMN and CNN were 1.77 and 0.88 ng/mL and 5.36 and 2.65 ng/mL, correspondingly, through the entire range of 0.1-1.0 µg/mL for DMN and CNN. The linearity was perfectly determined through the higher values of the correlation coefficient ranging from 0.9997 to 0.9999 for both direct and synchronous methods. The precision of the proposed methods was also confirmed via the lower values of the standard deviation which ranged from 0.39 to 1.11. The technique was expanded to analyze this mixture in combined tablets and laboratory-prepared mixtures. The method validation was done depending on the international conference on harmonization (ICH) recommendations. An analysis of the statistical data revealed a high agreement between the proposed data and the comparison methodology. Three different assessment methods demonstrated the greenness of the technique.
Topics: Cinnarizine; Dimenhydrinate; Hydrochloric Acid; Laboratories; Orphenadrine; Spectrometry, Fluorescence
PubMed: 37599333
DOI: 10.1038/s41598-023-40559-x -
Nature Reviews. Disease Primers May 2016Meniere's disease (MD) is a disorder of the inner ear that causes vertigo attacks, fluctuating hearing loss, tinnitus and aural fullness. The aetiology of MD is... (Review)
Review
Meniere's disease (MD) is a disorder of the inner ear that causes vertigo attacks, fluctuating hearing loss, tinnitus and aural fullness. The aetiology of MD is multifactorial. A characteristic sign of MD is endolymphatic hydrops (EH), a disorder in which excessive endolymph accumulates in the inner ear and causes damage to the ganglion cells. In most patients, the clinical symptoms of MD present after considerable accumulation of endolymph has occurred. However, some patients develop symptoms in the early stages of EH. The reason for the variability in the symptomatology is unknown and the relationship between EH and the clinical symptoms of MD requires further study. The diagnosis of MD is based on clinical symptoms but can be complemented with functional inner ear tests, including audiometry, vestibular-evoked myogenic potential testing, caloric testing, electrocochleography or head impulse tests. MRI has been optimized to directly visualize EH in the cochlea, vestibule and semicircular canals, and its use is shifting from the research setting to the clinic. The management of MD is mainly aimed at the relief of acute attacks of vertigo and the prevention of recurrent attacks. Therapeutic options are based on empirical evidence and include the management of risk factors and a conservative approach as the first line of treatment. When medical treatment is unable to suppress vertigo attacks, intratympanic gentamicin therapy or endolymphatic sac decompression surgery is usually considered. This Primer covers the pathophysiology, symptomatology, diagnosis, management, quality of life and prevention of MD.
Topics: Antiemetics; Audiometry; Benzodiazepines; Catheter Ablation; Dimenhydrinate; Ear, Inner; Endolymph; Ganglia, Sensory; Hearing Loss; Humans; Magnetic Resonance Imaging; Meclizine; Meniere Disease; Promethazine; Quality of Life; Tinnitus; Vertigo
PubMed: 27170253
DOI: 10.1038/nrdp.2016.28 -
Wiener Klinische Wochenschrift May 2016The efficacy and safety of the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg in the treatment of vertigo of various origins have been investigated in... (Observational Study)
Observational Study
The efficacy and safety of the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg in the treatment of vertigo of various origins have been investigated in a prospective, noninterventional study involving private practices throughout Germany. A total of 1275 patients with an average age of 61.2 years participated in the study. The vertigo symptoms, measured by a validated mean vertigo score (primary efficacy endpoint) improved by 61 % in the course of the observational period (median: 6 weeks). Concomitant symptoms frequently associated with vertigo such as nausea, vomiting and tinnitus were also markedly reduced by 84, 85 and 51 %, respectively. Overall efficacy has been rated by the physicians as 'very much improved' or 'much improved' in 95 % of the patients. A total of 47 patients (3.7 %) reported 51 adverse drug reactions (all nonserious). The results indicate a good tolerability and efficacy of the fixed combination of cinnarizine and dimenhydrinate in the treatment of vertigo in daily medical practice, which is in line with previous findings of numerous interventional, randomised, double-blind, controlled clinical trials.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antiemetics; Cinnarizine; Dimenhydrinate; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Histamine H1 Antagonists; Humans; Male; Middle Aged; Prevalence; Risk Factors; Sex Distribution; Treatment Outcome; Vertigo; Young Adult
PubMed: 26659910
DOI: 10.1007/s00508-015-0905-5 -
Anesthesia and Analgesia Apr 1996Dimenhydrinate, an H1-receptor antagonist, has been used to both prevent and treat postoperative vomiting (POV) in children for several decades. However, its... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
Dimenhydrinate, an H1-receptor antagonist, has been used to both prevent and treat postoperative vomiting (POV) in children for several decades. However, its effectiveness for POV after strabismus surgery remains anecdotal. This study was designed to determine the effectiveness and side effects of dimenhydrinate for the prevention of POV in children after strabismus surgery. Eighty ASA physical status I or II children, ages 1-12 yr inclusive, who were undergoing strabismus surgery, were prospectively and randomly allocated to receive either dimenhydrinate 0.5 mg/kg intravenously (n = 40) or placebo (n = 40) at induction of anesthesia. The incidence of POV and the times to arousal (and discharge from the recovery room and hospital) were recorded postoperatively in a double blinded manner. For 24 h after discharge from the hospital, all emetic episodes and medications given were recorded by the parents. Demographic data did not differ between the groups. Children who received dimenhydrinate had significantly less POV both inhospital (10%) and overall (30%) than those who received placebo (in-hospital 38%, P < 0.008; overall 65%, P < 0.003). The times to arousal and discharge from the hospital did not differ between the two groups. Dimenhydrinate (0.5 mg/kg) is an effective, safe, and inexpensive antiemetic in children undergoing strabismus surgery. It significantly reduces the incidence of vomiting for 24 h postoperatively and is not associated with prolonged sedation or other adverse effects.
Topics: Antiemetics; Child; Child, Preschool; Dimenhydrinate; Humans; Infant; Strabismus; Time Factors; Vomiting
PubMed: 8615488
DOI: 10.1097/00000539-199604000-00009 -
Pakistan Journal of Pharmaceutical... Jan 2021Development of dimenhydrinate (DMN) emulgel formulation has been described in this work with enhanced permeation for transdermal delivery of DMN for effective management...
Development of dimenhydrinate (DMN) emulgel formulation has been described in this work with enhanced permeation for transdermal delivery of DMN for effective management of motion sickness. Various DMN emulgel formulations were prepared using central composite design in response surface methodology. Propylene glycol and olive oil were used in varying ratios as permeation enhancers along-with carbopol-934 as gelling agent. Prepared formulations were evaluated by physico-chemical properties, stability and Fourier transform infrared spectroscopy (FTIR) studies. In-vitro drug release was studied using cellophane membrane. Formulation F2 showed maximum drug permeation following diffusion-based release mechanism and was used in further studies. Rat skin was used in Franz cell for ex-vivo studies to determine various permeation kinetic parameters. FTIR studies provided no evidence of chemical interaction between DMN and polymers used, whereas molecular docking revealed formation of a stable complex in the presence of aqueous environment with stable intermolecular binding and the complex was well hydrated. No evidence of skin irritation was observed in human volunteers following application of the optimized formulation. Histopathology data of the rat skin showed a decreased proliferation of the lymphocytes whereas monocytes were induced. In conclusion, combination of propylene glycol and olive oil was successfully employed for delivery of DMN through transdermal route with good permeability and prolonged release time that can be highly beneficial in treating motion sickness in unusual circumstances.
Topics: Administration, Cutaneous; Animals; Antiemetics; Dimenhydrinate; Drug Delivery Systems; Emulsions; Gels; Molecular Docking Simulation; Motion Sickness; Olive Oil; Propylene Glycol; Rats; Skin; Skin Absorption; Spectroscopy, Fourier Transform Infrared
PubMed: 34275848
DOI: No ID Found -
Medical Technicians Bulletin 1955
Topics: Dimenhydrinate; Food; Humans
PubMed: 13223126
DOI: No ID Found -
Clinical Autonomic Research : Official... Jun 2007The purpose of this study was to examine the effect of dimenhydrinate on resting muscle sympathetic nerve activity (MSNA), the vestibulosympathetic reflex, and the... (Randomized Controlled Trial)
Randomized Controlled Trial
The purpose of this study was to examine the effect of dimenhydrinate on resting muscle sympathetic nerve activity (MSNA), the vestibulosympathetic reflex, and the baroreflexes. Sixteen subjects participated in two double-blinded studies that measured mean arterial pressure (MAP), heart rate (HR), and MSNA responses before and after oral administration of dimenhydrinate (100 mg) or a placebo. In study one, 3 min of head-down rotation (HDR) was performed to engage the otolith organs. Dimenhydrinate (n = 10) did not alter resting MSNA, MAP, or HR. HDR increased MSNA before (Delta5 +/- 1 bursts/min; P < 0.01) and after (Delta4 +/- 1 bursts/min; P < 0.01) drug administration, but these responses were not different from the placebo (n = 6). In study two, 4 min of lower body negative pressure (LBNP) at -30 mmHg was performed. During the third min of LBNP, HDR was performed. MSNA increased during the first 2 min of LBNP before (Delta13 +/- 2 bursts/min; P < 0.01) and after (Delta14 +/- 2 bursts/min; P < 0.01) dimenhydrinate. HDR combined with LBNP increased MSNA further during the third min of LBNP (Delta18 +/- 2 bursts/min before and Delta17 +/- 2 bursts/min after dimenhydrinate; P < 0.01). These responses were not significantly different from the placebo. In contrast, HR responses to LBNP during the dimenhydrinate trial were increased when compared to all other trials (Delta5 +/- 1 beats/min; P < 0.01). These results indicate that dimenhydrinate augments heart rate responses to baroreceptor unloading, but does not alter resting MSNA, the sympathetic baroreflexes, or the vestibulosympathetic reflex.
Topics: Adult; Autonomic Nervous System; Baroreflex; Blood Pressure; Dimenhydrinate; Double-Blind Method; Female; Head-Down Tilt; Heart Rate; Humans; Lower Body Negative Pressure; Male; Parasympathetic Nervous System; Posture; Reflex; Sympathetic Nervous System; Vestibule, Labyrinth
PubMed: 17530457
DOI: 10.1007/s10286-007-0417-0